Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 171 results for "wallachbeth capital llc"

VistaGen Completes $10 Million Public Offering
Financial Buzz

VistaGen Completes $10 Million Public Offering

Chardan Capital Markets, LLC and WallachBeth Capital, LLC acted as joint book running managers for the offering. The shares and warrants described above were offered by VistaGen pursuant to a registration statement previously filed with, and ... PR Newswire, 2 months ago
[x]  
American Banking News - Forex

WallachBeth Capital Cuts Uniqure NV (QURE) Price Target to $35.00

Uniqure NV (NASDAQ:QURE) had its target price dropped by investment analysts at WallachBeth Capital from $60.00 to $35.00 in a research note issued on Wednesday. The brokerage presently has a buy rating on the stock. WallachBeth Capital's price ...
 WKRB News1 month ago Chardan Capital Reiterates Buy Rating for uniQure NV (QURE)  WKRB News1 week ago Spark Investment Management LLC Has $3,516,000 Stake in Uniqure NV (QURE)  WKRB News1 month ago Brean Capital Reiterates Buy Rating for Trevena Inc (TRVN)  American Banking News - Forex2 months ago
[x]  
Zolmax News

Vivus Inc. (VVUS) PT Set at $2.80 by WallachBeth Capital

Vivus Inc. (NASDAQ:VVUS) received a $2.80 target price from research analysts at WallachBeth Capital in a research report issued to clients and investors on Monday. The brokerage presently has a a buy rating on the biopharmaceutical company's ...
 WKRB News3 days ago Vivus Inc. (VVUS) Given a $2.80 Price Target at WallachBeth Capital  American Banking News - Forex3 days ago VIVUS, Inc. (VVUS) Stock Rating Reaffirmed by JPMorgan Chase & Co.  American Banking News - Forex1 month ago
[x]  
American Banking News

Esperion Therapeutics Inc. (ESPR) Rating Lowered to Hold at WallachBeth Capital

WallachBeth Capital lowered shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 1.3289% during trading on Tuesday, reaching $11.0413. The company's stock had a trading volume of 258,178 ...
 Mideast Time2 weeks ago Esperion Therapeutics Inc. (ESPR) Shares Bought by A.R.T. Advisors LLC  Mideast Time1 week ago Esperion Therapeutics Inc. (ESPR) Downgraded to Hold at WallachBeth Capital  American Banking News - Stock Ratings2 weeks ago WallachBeth Capital Lowers Esperion Therapeutics Inc. (ESPR) to Hold  WKRB News3 weeks ago
[x]  

Amici Capital LLC Acquires 642,120 Shares of Otonomy Inc. (OTIC)

Amici Capital LLC increased its stake in shares of Otonomy Inc. (NASDAQ:OTIC) by 1,212.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 695,061 shares of the ...
 Mideast Time1 week ago Otonomy Inc (OTIC) Shares Sold by Tiverton Asset Management LLC  WKRB News3 weeks ago Otonomy Inc (OTIC) Shares Sold by State Street Corp  WKRB News1 month ago

WallachBeth Capital Begins Coverage on Otonomy Inc (OTIC)

WallachBeth Capital assumed coverage on shares of Otonomy Inc (NASDAQ:OTIC) in a research note issued to investors on Thursday morning. The firm issued a buy rating and a $29.00 price objective on the biopharmaceutical company's stock. Several large ...
 Mideast Time1 month ago Otonomy Inc (OTIC) Now Covered by Analysts at WallachBeth Capital  American Banking News - Stock Ratings2 months ago Otonomy Inc (OTIC) Coverage Initiated by Analysts at WallachBeth Capital  WKRB News2 months ago

Sucampo Pharmaceuticals (SCMP) Buy Rating Reiterated at Roth Capital

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)s stock had its buy rating reaffirmed by analysts at Roth Capital in a report released on Tuesday. A number of other brokerages have also recently issued reports on SCMP. Zacks Investment Research cut ...
 American Banking News - Earnings1 week ago Sucampo Pharmaceuticals Inc. (SCMP) Given Buy Rating at Roth Capital  WKRB News2 weeks ago Mizuho Reiterates Buy Rating for Sucampo Pharmaceuticals Inc. (SCMP)  American Banking News - Earnings2 weeks ago Mizuho Reaffirms Buy Rating for Sucampo Pharmaceuticals Inc. (SCMP)  Mideast Time2 weeks ago
[x]  
Pensions and Investments Online

Commodities have some investors saying no

Institutional investors are wondering whether investing in commodities is worth the trouble, as the asset class has suffered an annualized return of -6.46% in the 10 years through June 30. Indeed, the Bloomberg Commodity index has been negative ...
 Pensions and Investments Online3 days ago

Clovis Oncology Inc. (CLVS) Shares Sold by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board reduced its stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) by 62.8% during the first quarter, Holdings Channel reports. The firm owned 26,500 shares of the biopharmaceutical company's stock after selling ...
 Mideast Time1 week ago Clovis Oncology's (CLVS) Hold Rating Reiterated at Credit Suisse Group AG  WKRB News1 week ago Clovis Oncology Inc (CLVS) Receives Buy Rating from Stifel Nicolaus  WKRB News3 weeks ago Vetr Inc. Downgrades Clovis Oncology Inc (CLVS) to Hold  American Banking News1 month ago

Weekly Analysts Ratings Changes for Esperion Therapeutics (ESPR)

by in Analyst Articles - Company Sum, Investing A number of firms have modified their ratings and price targets on shares of Esperion Therapeutics (NASDAQ: ESPR) recently: 7/6/2016 Esperion Therapeutics had its sell rating reaffirmed by ...
 SleekMoney1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - wallachbeth capital llc
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less